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1. Introduction
In the healthcare scientific environment, nowadays, researchers are inspired by endogenous 
springs of molecules that can be reinterpreted, better understood, or completely reconsidered 
in their function and ability to sustain the human organism in maintaining its homeostasis [1].
Melatonin is such a tremendous molecule acting in the center of the integrative molecular 
mechanisms of the body, based on interlinkages of the regulatory systems: neural, endocrine, 
immune, and genetic, all embodying the uniqueness of human architecture [1, 2].
The endogenous indole system represented by biomolecules with indole structure such as 
tryptophan, serotonin, and, above all, melatonin conducts the integration mechanisms of the 
organisms in the great informational variety of the environment. Melatonin is responsible for 
coordinating and synchronizing the expression of the most important physiological effects of 
the biological rhythm, imposes an order of the biochemical systems functionality and, glob-
ally, depicts the molecular logic of living [2, 3].
The indole ring is considered by scientists as a “privileged” biological structure [4, 5], due to 
its outstanding ability to form organic active compounds with different affinities for endog-
enous receptors, mainly for G protein-coupled receptors [6]. The indole structure is widely 
found at all levels of the biological systems as an important component of the biomolecules 
and natural products, such as the alkaloids from ergot, essential tryptophan amino acid, sero-
tonin, neuromediator, and melatonin, the main hormone secreted by the pineal gland. As a 
consequence of its biological effects, the indole nucleus is present in the structure of many 
marketed medicines [7–10] or dietary supplements [11–13], as well as in the prototypes of 
some drugs that are currently under development.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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As a constitutive element of proteins, the essential indole amino acid, tryptophan, has the 
most pronounced hydrophobic character of all the amino acids and forms a specific hydro-
phobic environment that contributes to the stabilization of the endogenous protein structure, 
special characteristics regarding membrane fluidity and transmembrane potential [14, 15]. 
Also, tryptophan is one of the most important indolic endogenous precursors, being involved 
in the biosynthesis of all endogenous compounds with indole structure: the neurotransmit-
ter serotonin, the pineal hormone melatonin, the neuromodulator and neurotransmitter 
tryptamine, 5-hydroxytryptophan, and 5-hydroxyindoleacetic acid, as also in the activity of 
some specific enzymes, cytochrome c peroxidase. Tryptophan depletion is part of the cyto-
toxic process and antiproliferative cellular mechanism mediated by γ-interferon. Low serum 
tryptophan concentrations are clinically correlated with the appearance of some pathological 
infectious, autoimmune, and, not the last, malignant processes [16–18].
Tryptophan is the precursor of serotonin, a neurotransmitter with indole structure, with vast 
biological effects. Emergence of imbalances in the serotoninergic metabolism determines the 
etiology and pathological neuropsychiatric and systemic disorders, including the develop-
ment of serotonin-secreting tumors [19–22]. Thus, a more complete overview of tryptophan 
and serotonin biochemistry and the precise relationships and interactions of these molecules 
with other endogenous constituents or structures may contribute to the therapeutic under-
standing and solving many psychiatric, autoimmune, and neoplastic disorders [23–25].
In particular, melatonin is an indole neurohormone synthesized mainly in the pineal gland, 
during the night, being also known as the darkness hormone. Melatonin is not exclusively 
synthesized by the pineal gland; the retina, the skin, and the gastrointestinal tract are only a 
few other tissues that produce high amounts of melatonin [26].
The direct precursor of melatonin is the serotonin, naturally synthesized in pinealocytes from 
L-tryptophan. The regulation system of the melatoninergic synthesis is complex, using central 
and autonomous pathways, so that there are many pathophysiologic situations where the 
melatonin secretion is deficient. The alteration of the melatoninergic circadian profile [27] is 
associated with the susceptibility, development, and evolution of a variety of pathologies, 
the highest incidence of cancer being registered in shift workers, which have a detrimental 
day-night alternation [28].
On the other hand, small fluctuations in the steady-state levels of the reactive oxygen and 
nitrogen species concentrations may play a key role in the intracellular signaling, uncontrolled 
increases of these highly reactive molecules leading to chain reactions mediated by free radi-
cals, which destroy, without discrimination, proteins, lipids, and DNA, resulting, ultimately, 
in cell death and being the primary or secondary cause of a wide range of diseases [29–35].
Melatonin was closely analyzed, under all biochemical aspects, considering its antioxidant 
mechanisms, intrinsic or modulatory at the level of antioxidant enzymes or in connected 
supplementary scavenging processes, and revealing a unique molecular antioxidant cascade. 
Its effects were interpreted in conjunction with other endogenous structures or assessed in 
controlled release formulations, aimed to enhance antioxidant processes and endogenous 
indole modulatory actions [36–38].
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This molecule was studied under very different circumstances, from interactions with DNA, 
in association with other therapeutic agents [39], using different animal models [40–45] and 
cell lines [46–48]. The current scientific interest focuses on revealing melatonin actions on 
major physiological process, as pregnancy or aging [49, 50], determining its modulatory abili-
ties on different stages of fetus evolution, on healthy aging mechanisms, and on preventing 
neurodegeneration, melatonin receptors being highly expressed at the placenta level, the 
BBB mainly by P-glycoprotein overexpression, mediating the mother-fetus interchanges and 
restricting the xenobiotic way to the fragile developing organism [51–53].
Melatonin also exerts different effects on the glucose metabolism, considering various targets: 
it stimulates glucose uptake in muscle cells by phosphorylation of insulin receptor substrate-1 
through MT2 signaling, MT2 receptors are expressed in hepatocytes, and melatonin therapy 
elevates glucose release from the liver [54].
The cardiovascular system physiological, pathophysiological, and molecular endogenous 
mechanisms are highly influenced by diurnal variations, circadian imbalances affecting gene 
and protein expression, cardiac remodeling, and promoting ischemia/reperfusion damage 
[55–64]. Desynchronizations are frequently registered in patients with hypertension, diabetes 
mellitus, obesity, and metabolic syndrome [65, 66].
Another important research field for melatonin and its derivatives is identifying predictive 
biomarkers meant to provide extensive control upon pathologic progression and therapy suc-
cess, markers that are as minimal invasive as possible and readily available [67–72].
Melatonin is the integrative molecule in the in vivo milieu of every living cell, mediating the 
integration complex mechanisms of the individual entity into the environment, synchronizes 
its cyclic processes, and depicts the circadian distribution of physiological and behavioral 
processes.
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